Chain Bridge I (NASDAQ:CBRG) announced this morning that it has signed a letter of intent (LOI) to combine with an unnamed target company.
Shareholders will have this to consider as they vote at a May 5 special meeting to extend the SPAC’s transaction deadline from May 15 to November 15. But, Chain Bridge I has not given them much more to chew on.
It aimed to combine with an innovative technology company with US government contracts when it IPO’d in November 2021, but has given no details about this potential target’s sector or business.
Chain Bridge I has also not yet pledged a contribution to its trust in connection with this extension and has stated its pro rata trust value current sits at about $10.44. The SPAC’s shares last closed at $10.46. This morning’s filing also clarified that the record date for the vote is to be April 4.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...